Soleno Therapeutics And Acadia Pharmaceuticals: Hope For Prader-Willi Families

Core Insights - The article discusses the late-stage trials of Acadia Pharmaceuticals and Soleno Therapeutics in the treatment of Prader-Willi Syndrome (PWS), highlighting the differences in their development stages and market positions [2][11]. Company Overview - Acadia Pharmaceuticals is an established commercial stage company with a market cap of approximately $4.53 billion as of January 21, 2024, while Soleno Therapeutics is a clinical stage company with a market cap of around $1.33 billion [4][5]. - Acadia's marketed therapies include NUPLAZID and DAYBUE, generating quarterly revenues of approximately $149 million and $67 million, respectively [4]. Product Pipeline - Acadia's PWS candidate therapy, ACP-101, is currently in a Phase 3 study with an estimated completion date in June 2026 [4][9]. - Soleno's PWS therapy, DCCR (diazoxide choline), is the primary focus of the company and is further along in development, with plans to submit a New Drug Application (NDA) for DCCR in mid-2024 [5][10]. Clinical Trials and Results - Soleno's DCCR has shown significant improvements in hyperphagia and other behavioral parameters in its long-term safety extension study (C602), with a highly statistically significant difference compared to placebo [8][10]. - Acadia's ACP-101 is still enrolling patients and lacks a defined timeline for potential filing, putting it behind Soleno's DCCR in terms of development [9]. Market Performance - Soleno's share price experienced significant volatility, with a notable increase following positive results from Study C602, closing at $47.01 as of January 21, 2024 [10]. - Acadia is rated a "Buy" based on its underlying metrics, while Soleno is considered a "Hold" due to its limited pipeline beyond DCCR [11].